Cargando…

Neointimal hyperplasia persists at six months after sirolimus-eluting stent implantation in diabetic porcine

BACKGROUND: Observational clinical studies have shown that patients with diabetes have less favorable results after percutaneous coronary intervention compared with the non-diabetic counterparts, but its mechanism remains unclear. The aim of this study was to examine the changes of neointimal hyperp...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qi, Lu, Lin, Pu, LiJin, Zhang, RuiYan, Shen, Jie, Zhu, ZhengBing, Hu, Jian, Yang, ZhenKun, Chen, QiuJin, Shen, WeiFeng
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1892541/
https://www.ncbi.nlm.nih.gov/pubmed/17550588
http://dx.doi.org/10.1186/1475-2840-6-16
_version_ 1782133841115217920
author Zhang, Qi
Lu, Lin
Pu, LiJin
Zhang, RuiYan
Shen, Jie
Zhu, ZhengBing
Hu, Jian
Yang, ZhenKun
Chen, QiuJin
Shen, WeiFeng
author_facet Zhang, Qi
Lu, Lin
Pu, LiJin
Zhang, RuiYan
Shen, Jie
Zhu, ZhengBing
Hu, Jian
Yang, ZhenKun
Chen, QiuJin
Shen, WeiFeng
author_sort Zhang, Qi
collection PubMed
description BACKGROUND: Observational clinical studies have shown that patients with diabetes have less favorable results after percutaneous coronary intervention compared with the non-diabetic counterparts, but its mechanism remains unclear. The aim of this study was to examine the changes of neointimal hyperplasia after sirolimus-eluting stent (SES) implantation in a diabetic porcine model, and to evaluate the impact of aortic inflammation on this proliferative process. METHODS: Diabetic porcine model was created with an intravenous administration of a single dose of streptozotocin in 15 Chinese Guizhou minipigs (diabetic group); each of them received 2 SES (Firebird, Microport Co, China) implanted into 2 separated major epicardial coronary arteries. Fifteen non-diabetic minipigs with SES implantation served as controls (control group). At 6 months, the degree of neointimal hyperplasia was determined by repeat coronary angiography, intravascular ultrasound (IVUS) and histological examination. Tumor necrosis factor (TNF)-α protein level in the aortic intima was evaluated by Western blotting, and TNF-α, interleukin (IL)-1β and IL-6 mRNA levels were assayed by reverse transcription and polymerase chain reaction. RESULTS: The distribution of stented vessels, diameter of reference vessels, and post-procedural minimal lumen diameter were comparable between the two groups. At 6-month follow-up, the degree of in-stent restenosis (40.4 ± 24.0% vs. 20.2 ± 17.7%, p < 0.05), late lumen loss (0.33 ± 0.19 mm vs. 0.10 ± 0.09 mm, p < 0.001) by quantitative angiography, percentage of intimal hyperplasia in the stented area (26.7 ± 19.2% vs. 7.3 ± 6.1%, p < 0.001) by IVUS, and neointimal area (1.59 ± 0.76 mm(2 )vs. 0.41 ± 0.18 mm(2), p < 0.05) by histological examination were significantly exacerbated in the diabetic group than those in the controls. Significant increases in TNF-α protein and TNF-α, IL-1β and IL-6 mRNA levels were observed in aortic intima in the diabetic group. CONCLUSION: Neointimal hyperplasia persisted at least up to 6 months after SES implantation in diabetic porcine, which may be partly related to an exaggerated inflammatory response within the blood vessel wall. Our results provide theoretical support for potential direct beneficial effects of anti-diabetic and anti-inflammation medications in reducing the risk of restenosis after stenting.
format Text
id pubmed-1892541
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-18925412007-06-15 Neointimal hyperplasia persists at six months after sirolimus-eluting stent implantation in diabetic porcine Zhang, Qi Lu, Lin Pu, LiJin Zhang, RuiYan Shen, Jie Zhu, ZhengBing Hu, Jian Yang, ZhenKun Chen, QiuJin Shen, WeiFeng Cardiovasc Diabetol Original Investigation BACKGROUND: Observational clinical studies have shown that patients with diabetes have less favorable results after percutaneous coronary intervention compared with the non-diabetic counterparts, but its mechanism remains unclear. The aim of this study was to examine the changes of neointimal hyperplasia after sirolimus-eluting stent (SES) implantation in a diabetic porcine model, and to evaluate the impact of aortic inflammation on this proliferative process. METHODS: Diabetic porcine model was created with an intravenous administration of a single dose of streptozotocin in 15 Chinese Guizhou minipigs (diabetic group); each of them received 2 SES (Firebird, Microport Co, China) implanted into 2 separated major epicardial coronary arteries. Fifteen non-diabetic minipigs with SES implantation served as controls (control group). At 6 months, the degree of neointimal hyperplasia was determined by repeat coronary angiography, intravascular ultrasound (IVUS) and histological examination. Tumor necrosis factor (TNF)-α protein level in the aortic intima was evaluated by Western blotting, and TNF-α, interleukin (IL)-1β and IL-6 mRNA levels were assayed by reverse transcription and polymerase chain reaction. RESULTS: The distribution of stented vessels, diameter of reference vessels, and post-procedural minimal lumen diameter were comparable between the two groups. At 6-month follow-up, the degree of in-stent restenosis (40.4 ± 24.0% vs. 20.2 ± 17.7%, p < 0.05), late lumen loss (0.33 ± 0.19 mm vs. 0.10 ± 0.09 mm, p < 0.001) by quantitative angiography, percentage of intimal hyperplasia in the stented area (26.7 ± 19.2% vs. 7.3 ± 6.1%, p < 0.001) by IVUS, and neointimal area (1.59 ± 0.76 mm(2 )vs. 0.41 ± 0.18 mm(2), p < 0.05) by histological examination were significantly exacerbated in the diabetic group than those in the controls. Significant increases in TNF-α protein and TNF-α, IL-1β and IL-6 mRNA levels were observed in aortic intima in the diabetic group. CONCLUSION: Neointimal hyperplasia persisted at least up to 6 months after SES implantation in diabetic porcine, which may be partly related to an exaggerated inflammatory response within the blood vessel wall. Our results provide theoretical support for potential direct beneficial effects of anti-diabetic and anti-inflammation medications in reducing the risk of restenosis after stenting. BioMed Central 2007-06-05 /pmc/articles/PMC1892541/ /pubmed/17550588 http://dx.doi.org/10.1186/1475-2840-6-16 Text en Copyright © 2007 Zhang et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Investigation
Zhang, Qi
Lu, Lin
Pu, LiJin
Zhang, RuiYan
Shen, Jie
Zhu, ZhengBing
Hu, Jian
Yang, ZhenKun
Chen, QiuJin
Shen, WeiFeng
Neointimal hyperplasia persists at six months after sirolimus-eluting stent implantation in diabetic porcine
title Neointimal hyperplasia persists at six months after sirolimus-eluting stent implantation in diabetic porcine
title_full Neointimal hyperplasia persists at six months after sirolimus-eluting stent implantation in diabetic porcine
title_fullStr Neointimal hyperplasia persists at six months after sirolimus-eluting stent implantation in diabetic porcine
title_full_unstemmed Neointimal hyperplasia persists at six months after sirolimus-eluting stent implantation in diabetic porcine
title_short Neointimal hyperplasia persists at six months after sirolimus-eluting stent implantation in diabetic porcine
title_sort neointimal hyperplasia persists at six months after sirolimus-eluting stent implantation in diabetic porcine
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1892541/
https://www.ncbi.nlm.nih.gov/pubmed/17550588
http://dx.doi.org/10.1186/1475-2840-6-16
work_keys_str_mv AT zhangqi neointimalhyperplasiapersistsatsixmonthsaftersirolimuselutingstentimplantationindiabeticporcine
AT lulin neointimalhyperplasiapersistsatsixmonthsaftersirolimuselutingstentimplantationindiabeticporcine
AT pulijin neointimalhyperplasiapersistsatsixmonthsaftersirolimuselutingstentimplantationindiabeticporcine
AT zhangruiyan neointimalhyperplasiapersistsatsixmonthsaftersirolimuselutingstentimplantationindiabeticporcine
AT shenjie neointimalhyperplasiapersistsatsixmonthsaftersirolimuselutingstentimplantationindiabeticporcine
AT zhuzhengbing neointimalhyperplasiapersistsatsixmonthsaftersirolimuselutingstentimplantationindiabeticporcine
AT hujian neointimalhyperplasiapersistsatsixmonthsaftersirolimuselutingstentimplantationindiabeticporcine
AT yangzhenkun neointimalhyperplasiapersistsatsixmonthsaftersirolimuselutingstentimplantationindiabeticporcine
AT chenqiujin neointimalhyperplasiapersistsatsixmonthsaftersirolimuselutingstentimplantationindiabeticporcine
AT shenweifeng neointimalhyperplasiapersistsatsixmonthsaftersirolimuselutingstentimplantationindiabeticporcine